Pharmaceutical firm Eli Lilly and the Food and Drug Administration allowed a single 79-year-old man to receive retatrutide, Lilly’s still-unapproved obesity drug, through the FDA’s expanded access pathway. The request was made in April, according to STAT, which attributed the information to three people familiar with the matter who were not named because they feared reprisals.
That pathway, often called compassionate use, is not a general early-access lane for high-demand medicines. The FDA says expanded access is meant for patients with a serious or immediately life-threatening disease or condition who cannot enroll in a clinical trial, lack comparable or satisfactory treatment options, and whose potential benefit justifies the risk. The agency also says the access must not interfere with trials needed to support approval.
That is what turns a one-patient case into a governance problem. Retatrutide is one of the most closely watched assets in the obesity market. Lilly says the drug is not FDA-approved, remains investigational, and is legally available only through Lilly’s clinical trials.
Sponsored · Selkirk Copper Mines
THE patient
STAT reported that the patient was a 79-year-old man and that the case drew attention from senior health officials, which the outlet framed as a sign the recipient may have been well connected. A senior NIH clinician reportedly requested the drug for refractory obesity with obstructive sleep apnea and pulmonary hypertension, according to follow-on coverage summarizing the story.
The identity of the patient remains unconfirmed.
The news site said it asked the White House whether the patient was President Donald Trump, who was 79 when the reported April request was made and turned 80 in June. The Daily Beast later reported that White House spokesperson Kush Desai denied Trump received the drug. The White House’s Rapid Response account also denied it publicly, according to The Daily Beast.
The White House had already released a physician memo in May saying Trump remained in “excellent health,” with strong cardiac, pulmonary, neurological, and overall physical function. Reuters reported that the memo listed Trump at 238 pounds and included advice on diet, physical activity, and ongoing weight management.
Sponsored · Cambria Gold Mines
However, the memo does not resolve the retatrutide question. The reported application details and the patient’s identity are not public, and HHS did not confirm the patient’s name in response to STAT’s inquiry, according to The Daily Beast.
Retatrutide
Retatrutide is not just another GLP-1 drug. Lilly describes it as a triple agonist because it targets GLP-1, GIP, and glucagon receptors. The company says the informal “GLP-3” label is scientifically inaccurate.
The drug has posted results that could reset expectations in the obesity market. Reuters reported in May that patients on the highest 12 mg dose lost an average of 28.3% of body weight over 80 weeks in a late-stage trial. More than 45% lost at least 30%, a level Lilly said rivals bariatric surgery.
Reuters also reported that Lilly hopes to launch retatrutide next year, subject to regulatory approval. In the same report, Lilly’s stock rose 1% after the data, while Novo Nordisk shares fell 0.7% by 1330 GMT.
That commercial context matters. Lilly already sells Zepbound and Mounjaro, while Novo Nordisk competes with Wegovy and Ozempic. Retatrutide could become the next escalation in a market where efficacy, tolerability, manufacturing scale, insurance coverage, and pricing all feed into investor expectations.
A one-off compassionate-use case does not change the drug’s clinical data. But it does create a fairness question around a medicine that millions of patients may want and few can legally access before approval.
Expanded access exists for hard cases where normal routes fail. But for a high-demand obesity drug, the optics are different. Obesity itself can be serious, and complications such as pulmonary hypertension can be life-threatening.
The issue is whether the public can understand why one patient qualified while the broader patient population remains locked out, most especially if that patient is the boss of the regulatory agency.
One Response
Being that Trump lies about his health — there’s no way he’s 6’3″ and weighs only 238 pounds, that would be on par with a totally fit NFL linebacker — just because the White House now denies he’s on it, we’re supposed to take that at face value? I’ve got a strait in the Middle East I’d like to sell you.